AbbVie (ABBV) said Tuesday that the European Commission granted marketing authorization to giant cell arteritis treatment Rinvoq for adult patients.
The approval was based on results from a phase 3 trial, which met its primary and key secondary endpoints, the company said.
The drug has been previously approved in seven other indications, including rheumatoid arthritis.
Giant cell arteritis is an inflammatory autoimmune disease of large blood vessels.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.